{"id":"https://openalex.org/W7225735582","doi":"https://doi.org/10.25251/tznaq106","title":"Treatment Patterns of Biologic Therapy in Hidradenitis Suppurativa: A Real-World Claims Analysis","display_name":"Treatment Patterns of Biologic Therapy in Hidradenitis Suppurativa: A Real-World Claims Analysis","publication_year":2026,"publication_date":"2026-11-10","ids":{"openalex":"https://openalex.org/W7225735582","doi":"https://doi.org/10.25251/tznaq106"},"language":"en","primary_location":{"id":"doi:10.25251/tznaq106","doi":"https://doi.org/10.25251/tznaq106","is_oa":true,"landing_page_url":"https://doi.org/10.25251/tznaq106","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.25251/tznaq106","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5092146267","display_name":"Vivian Shi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vivian Shi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161385018","display_name":"Jinan Liu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jinan Liu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161391169","display_name":"Lia Pizzicato","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lia Pizzicato","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056138219","display_name":"Chi-Chang Chen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chi-Chang Chen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5157755752","display_name":"Sidharth Gupta","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sidharth Gupta","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5115671215","display_name":"Janel Torsiello","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Janel Torsiello","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"6","first_page":"s897","last_page":"s897"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12731","display_name":"Hidradenitis Suppurativa and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12731","display_name":"Hidradenitis Suppurativa and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11553","display_name":"Acne and Rosacea Treatments and Effects","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12328","display_name":"Autoimmune and Inflammatory Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9635999798774719},{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.7968999743461609},{"id":"https://openalex.org/C2776002364","wikidata":"https://www.wikidata.org/wiki/Q341999","display_name":"Hidradenitis suppurativa","level":3,"score":0.6647999882698059},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.6055999994277954},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.5963000059127808},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5428000092506409},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5289999842643738},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.48579999804496765},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.46959999203681946},{"id":"https://openalex.org/C2779786854","wikidata":"https://www.wikidata.org/wiki/Q7444755","display_name":"Secukinumab","level":4,"score":0.4205999970436096},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.4018999934196472},{"id":"https://openalex.org/C2911221801","wikidata":"https://www.wikidata.org/wiki/Q2742406","display_name":"Biologic Agents","level":3,"score":0.3831000030040741},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.3723999857902527},{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.325300008058548},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.3174999952316284},{"id":"https://openalex.org/C187960798","wikidata":"https://www.wikidata.org/wiki/Q7631152","display_name":"Subgroup analysis","level":3,"score":0.3172000050544739},{"id":"https://openalex.org/C2908902254","wikidata":"https://www.wikidata.org/wiki/Q407954","display_name":"Compassionate Use","level":3,"score":0.3149999976158142},{"id":"https://openalex.org/C500440147","wikidata":"https://www.wikidata.org/wiki/Q701216","display_name":"Pharmacotherapy","level":2,"score":0.3127000033855438},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.2921000123023987},{"id":"https://openalex.org/C185926286","wikidata":"https://www.wikidata.org/wiki/Q1929812","display_name":"Systemic therapy","level":4,"score":0.2858999967575073},{"id":"https://openalex.org/C38180746","wikidata":"https://www.wikidata.org/wiki/Q1952580","display_name":"Multivariate analysis","level":2,"score":0.2791999876499176},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.2759000062942505},{"id":"https://openalex.org/C2778975655","wikidata":"https://www.wikidata.org/wiki/Q420305","display_name":"Ustekinumab","level":4,"score":0.27570000290870667},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.2599000036716461},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.259799987077713},{"id":"https://openalex.org/C2776215756","wikidata":"https://www.wikidata.org/wiki/Q412909","display_name":"Certolizumab pegol","level":4,"score":0.25060001015663147}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.25251/tznaq106","doi":"https://doi.org/10.25251/tznaq106","is_oa":true,"landing_page_url":"https://doi.org/10.25251/tznaq106","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.25251/tznaq106","doi":"https://doi.org/10.25251/tznaq106","is_oa":true,"landing_page_url":"https://doi.org/10.25251/tznaq106","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Introduction:":[0],"Biologic":[1],"therapies":[2,259,356],"are":[3],"increasingly":[4],"used":[5,51],"for":[6,199],"the":[7,44,90,103,227,310,341,383,399],"management":[8],"of":[9,84,116,122,131,186,207,296,335,353,385],"moderate":[10],"to":[11,224,276,294,361],"severe":[12],"hidradenitis":[13],"suppurativa":[14],"(HS).":[15],"However,":[16],"real-world":[17,318],"evidence":[18],"on":[19],"treatment":[20,27,264,286,338,370,387,401],"patterns":[21,99],"remains":[22],"limited.":[23],"This":[24,47],"study":[25,50],"evaluated":[26,140],"patterns,":[28],"including":[29],"adherence,":[30],"discontinuation,":[31,126],"switching,":[32,127],"augmentation,":[33],"and":[34,77,80,88,107,135,164,189,242,257,330,337,372,381],"persistence,":[35,331],"among":[36],"patients":[37,154,168,182,208,234,321,345],"with":[38,60,205,290,322,332,375],"HS":[39,66,323,400],"initiating":[40,324],"biologic":[41,94,150,170,216,307,325,363],"therapy":[42,171,217,326],"in":[43,226,377,388],"United":[45],"States.Methods:":[46],"retrospective":[48],"cohort":[49,229],"IQVIA":[52],"PharMetrics\u00ae":[53],"Plus":[54],"claims":[55,319],"data.":[56],"Adults":[57],"(\u226518":[58],"years)":[59],"\u22652":[61],"outpatient":[62],"or":[63,72],"\u22651":[64],"inpatient":[65],"diagnosis":[67],"who":[68,235,346],"first":[69],"initiated":[70,162,169],"adalimumab":[71,163],"secukinumab":[73,311],"between":[74],"January":[75],"2017":[76],"October":[78],"2024":[79],"had":[81,183,263,285],"\u226512":[82],"months":[83],"continuous":[85],"enrollment":[86],"before":[87,266],"after":[89],"index":[91,215,237,349],"date":[92],"(first":[93],"use)":[95],"were":[96,100,139,146,303],"included.":[97],"Treatment":[98],"assessed":[101],"over":[102],"12-month":[104,342],"post-index":[105],"period":[106],"included":[108,252],"regimen":[109],"type":[110],"(monotherapy":[111],"vs":[112,279],"combination":[113,178],"therapy),":[114,134],"number":[115],"fills,":[117],"days\u2019":[118,193,201],"supply,":[119,202],"adherence":[120,329],"(proportion":[121],"days":[123],"covered":[124],"[PDC]),":[125],"augmentation":[128,265,287,295,339],"(excluding":[129],"continuation":[130],"baseline":[132,275],"concomitant":[133],"persistence.":[136],"Time-to-event":[137],"outcomes":[138],"using":[141],"Kaplan-Meier":[142],"methods.":[143],"Subgroup":[144],"analyses":[145],"conducted":[147],"by":[148],"individual":[149],"agent.Results:":[151],"Among":[152,233,281,344],"4167":[153],"(mean":[155],"age,":[156],"37.9":[157],"years;":[158],"75.4%":[159],"female),":[160],"91.6%":[161],"8.4%":[165],"secukinumab.":[166],"Most":[167],"as":[172],"monotherapy":[173],"(81.1%),":[174],"whereas":[175,359],"18.9%":[176],"received":[177,245],"therapy.":[179],"During":[180],"follow-up,":[181,289],"a":[184,291],"mean":[185,195],"8.95":[187],"fills":[188],"approximately":[190],"269":[191],"total":[192],"supply;":[194],"PDC,":[196],"which":[197],"adjusts":[198],"overlapping":[200],"was":[203,230,313,357,364],"0.61,":[204],"39.0%":[206],"achieving":[209],"PDC":[210],"\u22650.80.":[211],"Overall,":[212],"58.4%":[213],"discontinued":[214,236,347],"within":[218],"12":[219],"months.":[220],"Kaplan-Meier\u2013estimated":[221],"median":[222,292],"time":[223,293],"discontinuation":[225,336],"full":[228],"245":[231],"days.":[232,298],"therapy,":[238],"8.3%":[239],"switched":[240],"biologics,":[241],"71.8%":[243],"subsequently":[244],"non-biologic":[246,354],"systemic":[247,355],"therapies;":[248],"non-mutually":[249],"exclusive":[250],"categories":[251],"antibiotics":[253],"(36.9%),":[254],"corticosteroids":[255],"(28.8%),":[256],"hormonal":[258],"(26.3%).":[260],"Additionally,":[261],"70.3%":[262],"discontinuation.":[267],"Concomitant":[268],"opioid":[269],"use":[270,352],"remained":[271],"relatively":[272],"unchanged":[273],"from":[274],"follow-up":[277],"(36.3%":[278],"35.0%).":[280],"persistent":[282],"patients,":[283],"93.1%":[284],"during":[288,340],"29":[297],"These":[299,366],"descriptive":[300],"treatment-pattern":[301],"findings":[302,367],"generally":[304],"similar":[305],"across":[306,398],"subgroups,":[308],"although":[309],"subgroup":[312],"substantially":[314],"smaller.Conclusions:":[315],"In":[316],"these":[317],"analyses,":[320],"demonstrated":[327],"suboptimal":[328],"high":[333],"rates":[334],"follow-up.":[343],"their":[348],"biologic,":[350],"subsequent":[351],"common,":[358],"switching":[360],"another":[362],"infrequent.":[365],"demonstrate":[368],"substantial":[369],"modification":[371],"limited":[373],"persistence":[374],"biologics":[376],"routine":[378],"clinical":[379],"practice":[380],"highlight":[382],"complexity":[384],"longitudinal":[386],"HS.":[389],"Additional":[390],"therapeutic":[391],"options":[392],"may":[393],"help":[394],"address":[395],"unmet":[396],"needs":[397],"pathway.":[402]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-11T00:00:00"}